In late December 2003, when Pfizer Inc. agreed to buy out Esperion Therapeutics Inc. for $1.3 billion - $35 per share, which amounted to a 54 percent premium to the average closing price during the previous 20 days - the pharmaceutical giant paid big for an opportunity that seemed even bigger. Read More
